Baker Julian's Form 4 filing
Kodiak Sciences Inc. (KOD) · filed Oct 1, 2021
- Accession no.
- 0001638599-21-000734
- Filed
- Oct 1, 2021, 4:58 PM ET
- Trade date
- Sep 29-30, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market purchases total $8.33M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baker JulianCIK 0001087939 | Director, 10% Owner |
| Baker FelixCIK 0001087940 | Director, 10% Owner |
| Baker Bros. Advisors LPCIK 0001263508 | Director, 10% Owner |
| Baker Brothers Life Sciences LPCIK 0001363364 | Director, 10% Owner |
| 667, L.P.CIK 0001551139 | Director, 10% Owner |
| Baker Bros. Advisors (GP) LLCCIK 0001580575 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 29, 2021 | Common Stock | MOption exerciseAcquired | +11,184 | $0.01F2 | +$111.84 | 1,154,580 | Indirect | |
| Sep 29, 2021 | Common Stock | FTax withholdingDisposed | −2 | $102.00F2 | −$204 | 1,154,578 | Indirect | |
| Sep 29, 2021 | Common Stock | MOption exerciseAcquired | +138,815 | $0.01F2 | +$1,388.15 | 13,439,808 | Indirect | |
| Sep 29, 2021 | Common Stock | FTax withholdingDisposed | −14 | $102.00F2 | −$1,428 | 13,439,794 | Indirect | |
| Sep 30, 2021 | Common Stock | PPurchaseAcquired | +86,932 | $95.83F10 | +$8,330,571.86 | 13,526,726 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
On September 29, 2021, 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") exercised warrants to purchase 11,184 and 138,815 shares of Common Stock of the Issuer, respectively, for $0.01 per share ("Prefunded Warrants"). 667 and Life Sciences paid the exercise price on a cashless basis, resulting in the Issuer withholding 2 and 14 shares of Common Stock for 667 and Life Sciences, respectively, of the Prefunded Warrant shares to pay the exercise price and issuing to 667 and Life Sciences the remaining 11,182 and 138,801 shares of Common Stock, respectively. The Issuer also paid $4.50 and $1.95 to 667 and Life Sciences, respectively, in cash in lieu of fractional shares. The Issuer's Board of Directors approved the exercise of the Prefunded Warrants by 667 and Life Sciences on the cashless basis described in this footnote in advance of such exercise.
Referenced by the price of 4 transactions in Table I.
- F7
Pursuant to Instruction 4(c)(iii), this response has been left blank.
Referenced by the price of 2 transactions in Table II.
- F10
The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $95.15 to $95.98, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Kodiak Sciences Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.